Alectinib shows promise for the treatment of refractory ALK-positive large B-cell lymphoma: a case report - Top-Institutions - MDSpire

Alectinib shows promise for the treatment of refractory ALK-positive large B-cell lymphoma: a case report

  • By

  • Atheer Alsulami

  • Roula Almufti

  • Saleem Eldadah

  • Yahya Al-Ghamdi

  • June 17, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, New York

    Key Differentiators

    • Hematology Oncology
    • Lymphoma

  • #2

    Mayo Clinic
    Mayo Clinic

    Rochester, Minnesota

    Key Differentiators

    • Hematology Oncology
    • Lymphoma

Original Source(s)

Alectinib shows promise for the treatment of refractory ALK-positive large B-cell lymphoma: a case report

  • by Atheer Alsulami, Roula Almufti, Saleem Eldadah, Yahya Al-Ghamdi

  • June 17, 2026

Related Content

Publisher Correction: Unsupervised risk factor identification across cancer types and data modalities via explainable artificial intelligence

Clinical outcomes of tebentafusp in metastatic uveal melanoma: a systematic review and single-arm meta-analysis

The quiet joy of being an oncologist